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Abstract 
Background and Aim: Severe combined immunodeficiency (SCID) has been described as the most severe form of 
primary immunodeficiency disorders (PID). The disease can be caused by mutations in more than 20 different 
genes with prevalence of 1 in 50000 to 100000 live births. In the present study, we described the protein domain 
position of variants in 14 main genes in patients with SCID. We also aimed to investigate the correlation between 
the variant distribution of protein domains and its pathogenicity and clinical outcome of the variant. Materials and 
Methods: Molecular genetic analysis including Sanger sequencing, targeted gene panel and whole exome 
sequencing were performed on 50 patients with SCID. Moreover, protein domains characteristics were extracted 
from different databases such as Uniprot and PDB and the reported mutations were obtained from HGMD and 
ENSEMBL databases. Results: Our results showed that the mortality rate had a significant correlation with 
severity of clinical manifestations in the patients (p-value=0.000). There was also a significant relationship 
between the protein type and mutation severity (p-value=0.001) and severity of clinical manifestations (p-
value=0.025). However, there was no significant relationship between the mortality rate and occurrence of 
mutations in different domains of proteins (p-value=0.304) and the severity of mutations (p-value= 0.586). 
Conclusion: In severe genetic diseases such as SCID, mutations in related genes have affected the structure of the 
protein enough to cause severe symptoms. However, there are differences in the pathogenicity of the mutations 
based on their location on the protein domains. In order to determine these variations and predict the outcome of 
mutations, it is necessary to use in silico and laboratory methods along with statistical and data mining tools to 
track these minor differences.  
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     Severe combined immunodeficiency (SCID) 
comprises a heterogeneous group of primary 
immunodeficiency disorders (PIDs) associated with 
severe decline in T and/or B lymphocytes. The 
overall prevalence of SCID varies between 1 in 
50000-100000 live births worldwide [1]. However, 
the actual number of PIDs cases is higher in the 
populations with a high rate of consanguineous 
marriage like Iran [2]. SCID disease commonly cause 
severe and repeated infections by opportunistic 
microorganisms, early onset skin rashes, cutaneous 
complications, persistent diarrhea, pneumonitis, oral 
candidiasis and failure to thrive (FTT) within the first 
year of life [3, 4]. Without immune reconstitution, 
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patients with SCID rarely survive beyond 6–12 
months [5]. However, they usually show a successful 
response to allogeneic hematopoietic stem cell 
transplantation (HSCT) [6]. Several contributing 
genes to SCID have been described so far [7]. The 
most common genes are CD3ε/δ/ζ,, IL2RG, JAK3, 
DCLRE1C, RAG1/ RAG2, ADA, PNP [8]. In Iran, 
the disease shows an autosomal recessive hereditary 
pattern in most of the cases. However, in populations 
with low consanguineous marriage rates, the pattern 
is mainly x-linked and most of the SCID cases are 
boys with mutations in IL2RG gene [9]. 
     Genetic variants can range from benign to 
severely pathogenic. The prediction of novel variants 
severity depends on various factors such as gene 
conservation, known pathogenic mutations, and 
protein‐level annotations. The best known in silico 
assessment tools include SIFT (sorting intolerant 
from tolerant) [10], PolyPhen [11] and CADD 
(combined annotation dependent depletion), though 
the implication of recently introduced analysis 
methods can provide more reliable results [12]. It can 
be difficult to identify crucial residues for preserving 
the domain's stability and function for some proteins 
[13]. However, by evaluating the frequency of the 
previously reported variants in particular domains, 
one can realize which domains are commonly 
correlated with disease severity. This information can 
be of use in determining whether a particular variant 
is pathogenic or benign [14]. 
     In the present study, we evaluated the protein 
domain distribution of SCID-causing mutations in 14 
causal genes found in our patients’ cohort. Our main 
goal was to study the correlation between mutations 
in different protein domains of SCID genes and 
severity of the disease. 
Methods 
Patients: The present study included 50 patients with 
SCID whose diagnosis was established according to 
the updated diagnostic criteria provided by the 
European Society for Immunodeficiencies 
(https://esid.org/Working-Parties/Registry/Diagnosis-
criteria) based on physical examination findings, 
survey on infection history, thoracic radiology for 
thymus gland detection, complete blood cell count 
(CBC), lymphocyte transformation test (LTT) for 
analysis of the lymphocyte function, detection of 
CD3,4,8,16,19,56 marker levels in blood and 
determination of serum immunoglobulin level (15, 
16). The clinical severity phenotype of patients with 
SCID was defined by having 2 of the following 
criteria: early-age onset of the symptoms (< 1 month), 
mortality (< 1 year), absent CD3+ or CD4+ or CD8 T+ 
cells, development of opportunistic infections, and 
development of severe infectious complications during 
the course of the disease (sepsis, central nervous 
system infections, osteomyelitis, and invasive bacterial 
infection) [17]. This study has been approved by the 
Ethics Committee of Pasteur Institute of Iran. 
Genetic diagnosis: The genetic examination was 
carried out for the patients leading to molecular 
diagnosis. Defects were explored in different SCID-
causing genes by Sanger sequencing, targeted gene 
panel (TGP) and whole exome sequencing (WES) [15, 
18]. The pathogenicity of disease variants was re-
assessed based on the updated guideline for 
interpretation of molecular sequencing presented by 
the American College of Medical Genetics and 
Genomics (ACMG) considering the allele frequency in 
the population database, immunological/functional 
data, familial segregation and parental genotype 
(https://www.acmg.net/). Prediction tools like SIFT, 
Polyphen and CADD were also used for prediction of 
mutation pathogenicity. Finally, the frame shift, 
nonsense, splice site and start losing mutations were 
considered as severe and missense variants as mild 
mutations. In order to find mutation distribution 
template in the previously reported variants, mutation 
histories were extracted from HGMD, ClinVar and 
Ensemble as genomic databases. The mutation 
severity was determined based on the effect of 
mutation on sequence and structure of proteins. Frame 
shift, nonsense, splicing and start loss mutations were 
considered as severe while non-frame shift and 
missense mutations as mild variants. 
Distribution of founded mutations in protein 
domains: In the present study, Uniprot 
(https://www.uniprot.org/) and PDB 
(https://www.rcsb.org/) database were used to find 
protein structures and domains. Proteins were first 
categorized into enzyme and receptor groups. 
Enzymatic protein domains were further divided into 
catalytic and non-catalytic groups. The catalytic 
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domain contains the part of the protein that has the 
active site of the enzyme. Receptor protein domains 
were also divided into three categories: extracellular, 
transmembrane and intracellular. 
Statistical analysis: Statistical analysis was 
performed using a commercially available software 
package (SPSS Statistics 22.0.0, SPSS, Chicago, 
Illinois). A p-value of <0.05 was considered to be 
statistically significant for all tests. 
Results 
Patients’ characteristics and genetic diagnosis: 
Demographic, clinical and laboratory data related to 
all 50 patients are presented in Tables 1, 2 and 3, 
respectively. The clinical manifestations were severe 
in 26 and mild in 24 patients. The characteristics of 
the patients’ genetic mutations have been described 
previously[15]. There were 44 different variants in 
the patients, 17 variants were previously reported in 
genomics databases (http://www.hgmd.cf.ac.uk, 
https://asia.ensembl.org) and 27 variants were novel 
variations. The pathogenic effect of the variants on 
corresponding proteins was severe in 27 and mild in 
23 patients. 
Distribution of the mutations in protein domains: 
As shown in figures 1 and 2, the mutations found in 
the present study are distributed in different domains 
of corresponding proteins. The gene mutations 
reported in this study including novel mutations are 
displayed alongside to previously reported mutations 
in each domain of the corresponding proteins. The 
frequency and distribution of variants in the protein 
domains were compared between previous reports 
and current study as displayed in Figure 3. 
Correlation between pathogenicity of the variants 
and their protein domain location: The results of 
statistical analysis show that there is no significant 
relationship between the occurrence of mutations in 
different domains of the proteins and mortality rate 
(χ2=4.845, df=1, and p-value=0.304(. No significant 
relationship was also found between the severity of 
mutations and the mortality rate (χ2=0.297, df=1, and 
p-value=0.586) while mortality has a significant 
correlation with severity of clinical manifestations; 
people with mild clinical manifestations had higher 
mortality rates (χ2=29.095, df=1, and p-
value=0.000). 
     The relationship between the mutation severity and 
protein type was statistically significant. Mutations in 
proteins with enzymatic activity were often more 
severe than in receptor proteins (χ2=12.013, df=1, and 
p-value=0.001). The relationship between protein type 
and the severity of clinical manifestations was also 
found to be significant in a way that people with 
mutations in genes with enzymatic activity displayed 
more severe clinical symptoms than those with 
mutations in receptor proteins (χ2=5.024, df=1, and p-
value=0.025).  
Based on domains of enzymatic proteins, there is no 
significant relationship between mutation severity in 
different domains of enzymatic mutation (χ2=3.601, 
df=1, and p-value=0.058) and receptor proteins 
(χ2=1.702, df=1, and p-value=0.762) meaning that the 
occurrence of mutations in these domains does not 
cause a change in the severity of the mutation. This 
lack of relationship is also true about the severity of 
clinical manifestations as well; no significant 
correlation exists between the severity of clinical 
manifestations and the enzymatic protein domains 
(χ2=1.298, df=1, and p-value=0.255) and receptor 
protein domains (χ2=1.664, df=1, and p-value=0.197). 
Table 1. Demographic data of the patients with SCID 
Demographic Features Number 
Gender 
Male, number (%) 29 (50) 
Female, number (%) 21 (50) 
Age of Onset (Month) 4.5.00 (0.00-94) 
Age of Diagnosis (Month) 5.00 (1.00-105) 
Diagnostic Delay (Month) 3.50 (0.00-10.00) 
Dead/Alive 38/50 
Table 2. Clinical characteristics of the patients with 
SCID 
Number (%) Clinical Characteristics 
17 (34%) Pneumonia, Number 
14 (28%) BCG-Osis, Number 
12 (24%) Oral candidiasis, Number 
11 (22%) FTT (Failure to thrive), Number 
19 (38%) Diarrhea, Number 
5 (10%) Skin infection, Number 
2 (4) Hives, Number 
1 (2%) Rash, Number 
2 (4%) Otitis, Number 
2 (4%) Urinary Tract Infections, Number 
23 (46%) Fever, Number 
11 (22%) LAP (Lymphadenopathy), Number 
12 (24%) Hepatomegaly, Number 
7 (14%) Splenomegaly, Number 
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Table 3. Laboratory features of the patients with SCID 
Title Mean (Range) 
CBC Test Results 
WBC(cell/ul) 5754.00 (2560-22305) 
Neut % 42.00 (17.50-68.75) 
Neut count 4145.00 (499.00-8778.0000) 
Lymph % 27.05 (3.27-48.17) 
Lymphocyte Count (%) 2197.62 (235.00-6850.88) 
CD-markers  
CD3% 21.00 (0.00-62.75) 
CD3  count 162.19 (0.00-3469.99) 
CD4% 8.00 (0.00-38.71) 
CD4  count 57.71 (0.00-1951.94)  
CD8% 3.35 (0.00-38.90) 
CD8  count 57.02 (0.00-2657.56)  
CD16-56% 17.34 (0.31-45.50) 
CD16 – 56 count 261.78 (2.90-1893.47) 
CD19% 1.35 (0.14-78.80) 
CD19 count 787.11 (1.15-4180.80) 
Serum levels of Immunoglobulins 
IgG(mg/dl)  316.00 (36.50-800.00) 
IgM(mg/dl)  56.00 (1.50-205.50) 
IgA(mg/dl) 5.50 (0.50-237.00) 
IgE(IU/ml)  23.70 (0.02-231.55) 
 
 
Figure 1. Mutation distribution in different domains of receptor proteins.  
Black font: Previously reported mutations; Red font: Mutations found in the present study; *: novel mutations found in the present 
study. 
 
Distribution of Disease-Causing Mutations …                                                                                              Shahbazi Z., et al. 
 
----------------------------------------------------------------------------------------------------------------------------------------------------------------- 
Archives of Medical Laboratory Sciences; Vol 5, No 4, Fall 2019                                                                                                             5 
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. 
 
Figure 2. Mutation distributions in different domains of enzyme proteins.  
Black font: Previously reported mutations; Red font: Mutations found in the present study; *novel mutations found in the present 
study. 
 
Figure 3. Frequency of mutations in different protein domains in the present study compared with previous reports 
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Discussion 
     In the present study, an attempt was made to 
investigate the mutation distribution in different 
protein domains and their consequences in clinical 
manifestations and survival prognosis of our patients 
with SCID. 
     Regarding the protein domains affected by gene 
mutations, genes with enzymatic roles such as ADA, 
DCLRE1C, JAK3, RAG1, RAG2 and ZAP70 are 
often mutated in catalytic or core enzyme domains, 
while genes acting as receptors such as CD3D, 
CD3E, IL7RA and IL2RG are often mutated in 
ligand binding or extra cellular domains (figures 1 
and 2). These findings were in line with our 
expectations according to the HGMD 
(http://www.hgmd.cf.ac.uk) and Atlas-Genetics-
Oncology (http://atlasgeneticsoncology.org) 
databases as well as the previous studies [19-22]. 
     Investigation of mutations distribution in different 
protein domains can help in pathogenicity 
interpretation of the changes. Finding a mutation in a 
domain with several previously reported pathogenic 
mutations could be an indication of the mutation 
pathogenicity, as most pathogenic mutations occur in 
essential domains of proteins. On the other hand, one 
way to find important protein domains is to look at 
the domains with previously reported pathogenic 
mutations [19-22]. 
     It may be inferred that proteins with enzymatic 
activity have a higher level of tolerance to missense 
variants. Some of the missense variants may be 
classified as SNPs and do not cause traceable clinical 
complications. This may be due to the maintenance 
of protein function despite conformational changes 
caused by missense variants. On the other hand, 
receptor proteins may be vulnerable to missense 
variants, which might justify why missense variants 
in receptor genes cause noticeable clinical 
complications. Although these variants may cause 
minor changes in the structure of the receptor 
protein, they may affect the protein function by 
changing their specific functional conformation. 
     The same explanation may be applied in 
interpreting the cause of increased severity of clinical 
manifestations in patients with enzymatic genes 
mutations. Due to the higher frequency of missense 
mutations in the receptor genes in the present study, 
there may be some residual activity in these proteins. 
This reduces the severity of manifestations in these 
patients compared to the patients with mutations in 
enzymatic genes because most of the mutations in 
the enzymatic genes were severe and led to a 
complete loss of function. 
     However, due to the small number of patients 
studied in the present study, no definitive conclusion 
can be drawn. In order to accurately investigate the 
effect of different variants on the structure of 
proteins, in silico studies are necessary considering 
the biological conditions of the living environment, 
the position of amino acids relative to each other and 
the characteristics of amino acids around the 
mutation. 
Conclusion 
     Since prediction of mutation pathogenicity is a 
critical step in genetic counseling, carrier detection, 
and prenatal diagnosis, using appropriate and 
different tools in interpreting these variants can 
increase the accuracy and certainty of the conclusion. 
One of the best tools in this field is to investigate in 
which vital domain of the protein the mutation 
occurred. This tool is also used in the ACMG 
guidelines. However, in the present study, we 
concluded that in addition to statistical studies, it is 
necessary to conduct in silico studies to determine 
the effect of mutation location on the disease severity 
and outcome.  
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